Chlamydia vaccine on the horizon after early clinical trial shows promise


Both formulations of the vaccine provoked an immune response but the vaccine with added liposomes performed better, producing more antibodies.

The presence of an immune response does not necessarily mean the vaccine will prevent someone from getting a disease so further trials are needed, researchers said.

Dr Helene Juel, clinical development scientist at the Statens Serum Institute and lead author of the study, said: “Studies of antibodies in mice have found that antibodies in the vagina are the first line of defence against chlamyia infection, which suggests they are key to how effective the new vaccine may be.”

Researchers say that vaccination may be the best way to tackle the chlamydia epidemic as national treatment and screening programmes have failed to reduce the number of cases.


Please enter your comment!
Please enter your name here